Exicure (XCUR) EBT Margin (2016 - 2024)

Exicure's (XCUR) quarterly EBT Margin came in at 165.8% in Q1 2024, down 294.04% on a QoQ basis from 85.45% in Q4 2022.

Exicure (XCUR) EBT Margin (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 8 years of EBT Margin data on file, last reported at 165.8% in Q1 2024.

Quarterly EBT Margin changed N/A year-over-year to 165.8% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 1938.6% (changed N/A YoY) and the FY2024 annual result came in at 1938.6%, changed N/A from the prior year.
EBT Margin fell to 165.8% in Q1 2024, from 85.45% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 652.74% in Q4 2021 to a low of 18062.03% in Q2 2021.
A 4-year average of 2289.46% and a median of 302.31% in 2022 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2020 — EBT Margin jumped 2342852 bps — and 2021, when it slumped 1797308 bps.
Tracing XCUR's EBT Margin over 4 years: stood at 9060.71% in 2020, then surged by 107 bps to 652.74% in 2021, then sank by 87 bps to 85.45% in 2022, then plunged by 294 bps to 165.8% in 2024.
The last three EBT Margin figures came in at 165.8% (Q1 2024), 85.45% (Q4 2022), and 255.95% (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Exicure	8.41 Mn	8.41 Mn	-	-

Download Data